Authors: C. David Mazer, M.D., Richard P. Whitlock, M.D., Ph.D., Dean A. Fergusson, Ph.D., M.H.A., Judith Hall, M.Sc., Emilie Belley-Cote, M.D., Katherine Connolly, M.D., Boris Khanykin, M.D., Alexander J. Gregory, M.D., Étienne de Médicis, M.D., Shay McGuinness, M.B., Ch.B., Alistair Royse, M.B., B.S., M.D., François M. Carrier, M.D., Paul J. Young, F.C.I.C.M., Ph.D., Juan C. Villar, M.D., Ph.D., Hilary P. Grocott, M.D., Manfred D. Seeberger, M.D., Stephen Fremes, M.D., François Lellouche, M.D., Ph.D., Summer Syed, M.D., Kelly Byrne, M.B., Ch.B., Sean M. Bagshaw, M.D., Nian C. Hwang, M.B., B.S., G.D.Acu., Chirag Mehta, M.D., Thomas W. Painter, M.B., Ch.B., Colin Royse, M.B., B.S., M.D., Subodh Verma, M.D., Ph.D., Gregory M.T. Hare, M.D., Ph.D., Ashley Cohen, M.Sc., Kevin E. Thorpe, M.Math., Peter Jüni, M.D., and Nadine Shehata, M.D., for the TRICS Investigators and Perioperative Anesthesia Clinical Trials Group*

Reference: N Engl J Med 2017; 377:2133-2144November 30, 2017DOI: 10.1056/NEJMoa1711818

BACKGROUND
The effect of a restrictive versus liberal red-cell transfusion strategy on clinical outcomes in patients undergoing cardiac surgery remains unclear.
METHODS
In this multicenter, open-label, noninferiority trial, we randomly assigned 5243 adults undergoing cardiac surgery who had a European System for Cardiac Operative Risk Evaluation (EuroSCORE) I of 6 or more (on a scale from 0 to 47, with higher scores indicating a higher risk of death after cardiac surgery) to a restrictive red-cell transfusion threshold (transfuse if hemoglobin level was

Pubmed ID: 29130845